Publicaciones (37) Publicaciones de MOISÉS GARCÍA ARENCIBIA

2021

  1. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease

    European Journal of Pharmacology, Vol. 895

2019

  1. Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells

    British Journal of Pharmacology, Vol. 176, Núm. 10, pp. 1361-1369

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

  2. Outbreak and Eradication of Tropical Rat Mite (Acari: Macronyssidae) in a European Animal Facility

    Journal of Medical Entomology, Vol. 55, Núm. 2, pp. 468-471

2017

  1. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

    Pharmacological Research

2016

  1. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Pharmacological Research, Vol. 110, pp. 205-215

  2. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2receptor ligands with antagonist/inverse agonist properties

    European Journal of Medicinal Chemistry, Vol. 112, pp. 66-80

2015

  1. Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity

    Cell Death and Differentiation, Vol. 22, Núm. 3, pp. 433-444

  2. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists

    European Journal of Medicinal Chemistry, Vol. 101, pp. 651-667

2014

  1. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 73, pp. 56-72

2013

  1. IGF-1 receptor antagonism inhibits autophagy

    Human Molecular Genetics, Vol. 22, Núm. 22, pp. 4528-4544

  2. Neuroprotective properties of standardized extracts of hypericum perforatum on rotenone model of parkinson's disease

    CNS and Neurological Disorders - Drug Targets, Vol. 12, Núm. 5, pp. 665-679

2012

  1. Autophagy and misfolded proteins in neurodegeneration

    Experimental Neurology, Vol. 238, Núm. 1, pp. 22-28

  2. Bim Inhibits Autophagy by Recruiting Beclin 1 to Microtubules

    Molecular Cell, Vol. 47, Núm. 3, pp. 359-370

  3. Mecanismo de acción de las hormonas.

    Endocrinología (Madrid : Médica Panamericana, 2001), pp. 11-22

2011

  1. Complex Inhibitory Effects of Nitric Oxide on Autophagy

    Molecular Cell, Vol. 43, Núm. 1, pp. 19-32

  2. Identification of virtual signal transducers and activators of transcription response elements in the human insulin receptor gene promoter

    Computational Biology and Chemistry, Vol. 35, Núm. 6, pp. 333-335

  3. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9-THCV in animal models of Parkinson's disease

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1495-1506

  4. TFEB links autophagy to lysosomal biogenesis

    Science, Vol. 332, Núm. 6036, pp. 1429-1433

2010

  1. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice

    PLoS ONE, Vol. 5, Núm. 7, pp. 1-15